| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.1638 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.2328 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.2478 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.2909 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3175 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3268 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3393 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3575 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3756 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3925 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.3958 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4209 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4264 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4269 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4492 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4567 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.4907 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5088 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5139 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5165 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5307 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5334 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5702 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5756 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5821 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5914 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.5915 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6092 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6126 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6188 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6241 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6423 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6479 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6485 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6510 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6615 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6772 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6793 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6857 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.6933 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7100 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7127 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7167 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7340 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7366 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7409 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7454 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7467 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7474 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7500 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7650 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7660 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7894 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7910 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7922 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7975 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7981 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.7987 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8002 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8025 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8047 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8117 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8229 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8236 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8309 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8335 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8441 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8537 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8568 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8590 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8602 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8750 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8752 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8809 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8824 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8832 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8873 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8901 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8929 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.8949 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9019 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9019 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9103 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9129 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9262 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9390 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9440 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9661 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9732 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9826 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9834 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9869 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 0.9994 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0000 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0029 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0037 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0099 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0137 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0174 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0249 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0265 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0533 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0591 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0608 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0736 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0737 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.0840 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1027 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1053 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1104 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1206 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1293 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1427 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1573 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1591 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1665 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1847 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1850 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1887 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1903 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.1911 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2182 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2297 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2338 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2367 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2597 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2710 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2712 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2874 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2948 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.2958 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3173 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3174 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3234 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3319 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3491 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3499 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3592 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3624 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3802 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.3880 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4077 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4132 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4153 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4220 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4335 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4385 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4735 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4758 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.4771 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5021 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5265 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5311 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5329 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5396 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5495 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.5656 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.6010 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.6171 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.6239 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.6696 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.6835 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7277 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7311 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7399 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7483 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7638 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7802 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.7938 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8054 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8131 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8134 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8210 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8349 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8372 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8446 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.8553 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.9572 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 1.9714 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.0554 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.0703 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.0803 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.1142 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.2938 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.3831 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 2.5032 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | phenylacetylglutamine | 3.1343 | scaled units | High-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|